Abstract
1 Chloroquine was given in 300 mg single doses as an i.v. infusion, an oral solution and as tablets at intervals of at least 56 days to 11 healthy volunteers. Concentrations of chloroquine and its metabolite desethylchloroquine were measured in plasma, erythrocytes and urine using h.p.l.c. 2 Chloroquine was detectable in all plasma samples up to 23 days and occasionally up to 52 days after dosage. Urinary concentrations were monitored up to 119 days. The disposition pattern was multiexponential reflecting extensive tissue binding of the drug. 3 After i.v. dosing the volume of distribution ranged from 116 to 285 l/kg and the apparent terminal half-life from 146 to 333 h. Total plasma clearance +/- s.d. was 712 +/- 166 ml/min and renal clearance 412 +/- 139 ml/min. The mean estimated urinary recovery of chloroquine was 47%, 42% and 46% after i.v., oral solution and tablets indicating nearly complete bioavailability. The corresponding figures for the metabolite were 7%, 10% and 12%. 4 The disposition of chloroquine in erythrocytes was parallel to that in plasma. The concentrations in erythrocytes were consistently 2 to 5 times higher than in plasma. 5 Subjective side effects like difficulties with swallowing and accommodation, diplopia and fatigue occurred during intravenous infusion and were closely related to plasma concentrations. No effect was seen on the electrocardiogram, mean arterial blood pressure and pulse rate. No adverse reactions were observed after the oral doses. High frequency audiometry did not reveal any significant hearing impairment for the group as a whole.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Adelusi S. A., Salako L. A. Improved fluorimetric assay of chloroquine in biological samples. J Pharm Pharmacol. 1980 Oct;32(10):711–712. doi: 10.1111/j.2042-7158.1980.tb13045.x. [DOI] [PubMed] [Google Scholar]
- Alván G., Ekman L., Lindström B. Determination of chloroquine and its desethyl metabolite in plasma, red blood cells and urine by liquid chromatography. J Chromatogr. 1982 Apr 16;229(1):241–247. doi: 10.1016/s0378-4347(00)86059-4. [DOI] [PubMed] [Google Scholar]
- Bergqvist Y., Domeij-Nyberg B. Distribution of chloroquine and its metabolite desethyl-chloroquine in human blood cells and its implication for the quantitative determination of these compounds in serum and plasma. J Chromatogr. 1983 Jan 14;272(1):137–148. doi: 10.1016/s0378-4347(00)86110-1. [DOI] [PubMed] [Google Scholar]
- Dwivedi G. S., Mehra Y. N. Ototoxicity of chloroquine phosphate. A case report. J Laryngol Otol. 1978 Aug;92(8):701–703. doi: 10.1017/s0022215100085960. [DOI] [PubMed] [Google Scholar]
- Frisk-Holmberg M., Bergkvist Y., Domeij-Nyberg B., Hellström L., Jansson F. Chloroquine serum concentration and side effects: evidence for dose-dependent kinetics. Clin Pharmacol Ther. 1979 Mar;25(3):345–350. doi: 10.1002/cpt1979253345. [DOI] [PubMed] [Google Scholar]
- HART C. W., NAUNTON R. F. THE OTOTOXICITY OF CHLOROQUINE PHOSPHATE. Arch Otolaryngol. 1964 Oct;80:407–412. doi: 10.1001/archotol.1964.00750040419009. [DOI] [PubMed] [Google Scholar]
- Lovering E. G., McGilveray I. J., McMillan I., Tostowaryk W. Comparative bioavailabilities from truncated blood level curves. J Pharm Sci. 1975 Sep;64(9):1521–1524. doi: 10.1002/jps.2600640921. [DOI] [PubMed] [Google Scholar]
- McChesney E. W., Fasco M. J., Banks W. F., Jr The metabolism of chloroquine in man during and after repeated oral dosage. J Pharmacol Exp Ther. 1967 Nov;158(2):323–331. [PubMed] [Google Scholar]